Research Analysts Set Expectations for CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Management issued their FY2029 EPS estimates for CRISPR Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $63.56 per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter in the prior year, the business earned ($1.41) earnings per share.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Barclays cut their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Bank of America lowered their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

CRSP opened at $41.29 on Wednesday. The company’s 50 day simple moving average is $46.63 and its 200-day simple moving average is $48.94. CRISPR Therapeutics has a one year low of $38.20 and a one year high of $91.10. The stock has a market capitalization of $3.52 billion, a P/E ratio of -14.59 and a beta of 1.68.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 1.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,382 shares of company stock valued at $2,744,179 over the last three months. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of CRISPR Therapeutics by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 78,692 shares of the company’s stock worth $4,250,000 after purchasing an additional 3,378 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of CRISPR Therapeutics by 14.0% in the second quarter. Commonwealth Equity Services LLC now owns 61,559 shares of the company’s stock valued at $3,325,000 after buying an additional 7,560 shares during the last quarter. Natixis Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 3.8% during the 2nd quarter. Natixis Advisors LLC now owns 10,906 shares of the company’s stock worth $589,000 after acquiring an additional 400 shares during the period. Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares during the last quarter. Finally, National Bank of Canada FI raised its stake in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares during the period. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.